Vonlerolizumab
Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134) . Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models[1].
Product Specifications
CAS Number
[1638935-72-4]
Product Name Alternative
Pogalizumab; MOXR 0916
UNSPSC
12352203
Target
Orexin Receptor (OX Receptor)
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vonlerolizumab.html
Purity
99.70
Solubility
10 mM in DMSO
Smiles
[Vonlerolizumab]
Molecular Weight
(145.26 kDa)
References & Citations
[1]Holay N, et al. INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering. J Immunother Cancer. 2025 May 21;13 (5) :e011524.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6349613-02 5x 0.1 mL
SNX25, ID (SNX25, Sorting nexin-25) (MaxLight 550)
Request Quote
View Details NBP2-72318PECY55 0.1 mL
Mouse Monoclonal DPP9 Antibody (OTI2E3) [PE/Cy5.5]
Request Quote
View Details